Company / Cash & Equivalents
FATE THERAPEUTICS INC Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$46.6M
FY2025
5-year range
$36.1M / $167.3M
FY2021-FY2025
Trend
+29.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents returned to growth in FY2025 after 3 years of decline, reaching $47M.
Based on SEC 10-K filings.
$47M in FY2025 with a 5-year CAGR of -14.1%.
Improved from $42M to $47M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -8.7%
- 5-Year CAGR
- -14.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -14.1%, indicating a declining trend.
- In FY2025, cash & equivalents increased 29.3% year-over-year.
- Peak cash & equivalents was recorded in FY2019.
- Lowest cash & equivalents in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 632.81 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $46.6M | +29.3% |
| FY2024 | $36.1M | -13.9% |
| FY2023 | $41.9M | -31.7% |
| FY2022 | $61.3M | -63.3% |
| FY2021 | $167.3M | +67.7% |
| FY2020 | $99.8M | -47.6% |
| FY2019 | $190.5M | +114.2% |
| FY2018 | $89.0M | +0.4% |
| FY2017 | $88.6M | +36.7% |
| FY2016 | $64.8M | +19.9% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026